KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Free Cash Flow (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Free Cash Flow for 8 consecutive years, with $20.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 22.73% to $20.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.0 million through Dec 2025, down 18.28% year-over-year, with the annual reading at $53.0 million for FY2025, 18.28% down from the prior year.
  • Free Cash Flow hit $20.0 million in Q4 2025 for Castle Biosciences, down from $25.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $36.1 million in Q3 2024 to a low of -$28.8 million in Q1 2023.
  • Historically, Free Cash Flow has averaged $1.4 million across 5 years, with a median of -$5.1 million in 2021.
  • Biggest five-year swings in Free Cash Flow: plummeted 740.88% in 2021 and later skyrocketed 352.48% in 2023.
  • Year by year, Free Cash Flow stood at -$6.1 million in 2021, then plummeted by 72.88% to -$10.5 million in 2022, then skyrocketed by 155.88% to $5.9 million in 2023, then skyrocketed by 341.97% to $25.9 million in 2024, then decreased by 22.73% to $20.0 million in 2025.
  • Business Quant data shows Free Cash Flow for CSTL at $20.0 million in Q4 2025, $25.0 million in Q3 2025, and $18.7 million in Q2 2025.